PVLA
Palvella Therapeutics, Inc.Company with tickers: PVLA
CIK
1583648
CUSIP
697947109
Shares Outstanding
14,342,844
13F Activity (30d)
150 filings
148 filers
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | — | ||||
| Revenue (ASC 606) | — | ||||
| Cost of Revenue | — | ||||
| Gross Profit | — | ||||
| Operating Expenses | $14,855,000 | USD | 2026-03-31 | 10-Q | 2026-05-07 |
| Research & Development | $9,334,000 | USD | 2026-03-31 | 10-Q | 2026-05-07 |
| Operating Income | $-14,855,000 | USD | 2026-03-31 | 10-Q | 2026-05-07 |
| Net Income | $-15,767,000 | USD | 2026-03-31 | 10-Q | 2026-05-07 |
| EPS (Basic) | $-1.20 | USD/shares | 2026-03-31 | 10-Q | 2026-05-07 |
| EPS (Diluted) | $-1.20 | USD/shares | 2026-03-31 | 10-Q | 2026-05-07 |